文献速递重症综合管理与镇静镇痛

重症患者右美托咪定与丙泊酚镇静及剂量相关90天死亡率:SPICE III随机对照试验的次要队列分析

Dexmedetomidine and Propofol Sedation in Critically Ill Patients and Dose-associated 90-Day Mortality: A Secondary Cohort Analysis of a Randomized Controlled Trial (SPICE III).
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01
一句话结论SPICE III次要分析:≤65岁用右美托咪定联合丙泊酚镇静者,优先增加丙泊酚剂量与调整后90天死亡率降低相关(HR 0.59),增加右美托咪定与死亡率升高相关(HR 1.30)。

该研究为SPICE III随机对照试验的次要队列分析,纳入1,177例随机接受右美托咪定并补充丙泊酚的患者,按年龄(>65岁或≤65岁)分层,采用双重分层分析及Cox回归评估镇静剂量与90天死亡率的关系。年轻患者(598/1,177,50.8%)达到可比镇静深度所需两种镇静药剂量均显著高于老年患者。在年轻患者中,右美托咪定固定输注速率0.54 μg/kg/h时,将丙泊酚输注速率递增至1.27 mg/kg/h与调整后死亡率降低相关(HR 0.59,95%CI 0.43-0.78,P<0.0001);而增加右美托咪定输注速率与调整后死亡率升高相关(HR 1.30,95%CI 1.03-1.65,P=0.029)。作者认为,≤65岁接受右美托咪定联合丙泊酚镇静的患者,优先增加丙泊酚剂量与90天死亡率降低相关,增加右美托咪定可能与死亡率升高相关。

要点

  • ≤65岁患者中,右美托咪定固定0.54 μg/kg/h时丙泊酚增至1.27 mg/kg/h与调整后90天死亡率降低相关(HR 0.59,95%CI 0.43-0.78,P<0.0001)。
  • ≤65岁患者中,增加右美托咪定输注速率与调整后90天死亡率升高相关(HR 1.30,95%CI 1.03-1.65,P=0.029)。
  • 年轻患者(598/1,177,50.8%)达到可比镇静深度所需右美托咪定和丙泊酚剂量均显著高于老年患者。
  • >65岁患者中,丙泊酚剂量递增至1.27 mg/kg/h(右美托咪定0.54 μg/kg/h)与调整后死亡率降低无显著关联。
  • 结论基于随机对照试验的次要队列分析,作者认为≤65岁联合镇静时优先增加丙泊酚剂量、增加右美托咪定可能伴随死亡率升高。

适用人群与场景

  • SPICE III试验中随机分配至右美托咪定组并补充使用丙泊酚的1,177例重症患者,按年龄>65岁或≤65岁分层。

研究设计与关键结果

  • 研究类型为SPICE III随机对照试验的次要队列分析,纳入1,177例随机接受右美托咪定并补充丙泊酚的患者,按年龄(>65岁或≤65岁)分层。
  • 年轻患者598/1,177(50.8%)达到可比镇静深度所需右美托咪定和丙泊酚剂量均显著高于老年患者。
  • 双重分层分析显示,在右美托咪定固定输注速率0.54 μg/kg/h时,丙泊酚输注速率递增至1.27 mg/kg/h与年轻患者调整后死亡率降低相关,老年患者无此关联。
  • 多变量回归模型显示,年轻患者中丙泊酚剂量递增与调整后90天死亡率降低相关(HR 0.59,95%CI 0.43-0.78,P<0.0001),模型调整基线风险及与右美托咪定剂量的交互作用。
  • 年轻患者中,增加右美托咪定输注速率与调整后90天死亡率升高相关(HR 1.30,95%CI 1.03-1.65,P=0.029)。

证据类型、等级与局限

  • 证据类型:随机对照试验(SPICE III,NCT01728558)的次要队列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,≤65岁接受右美托咪定联合丙泊酚镇静的患者,优先增加丙泊酚剂量与调整后90天死亡率降低相关;增加右美托咪定可能与死亡率升高相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: The SPICE III (Sedation Practice in Intensive Care Evaluation) trial reported significant heterogeneity in mortality with dexmedetomidine treatment. Supplemental propofol was commonly used to achieve desirable sedation. Objectives: To quantify the association of different infusion rates of dexmedetomidine and propofol, given in combination, with mortality and to determine if this is modified by age. Methods: We included 1,177 patients randomized in SPICE III to receive dexmedetomidine and given supplemental propofol, stratified by age (>65 or ⩽65 yr). We used double stratification analysis to produce quartiles of steady infusion rates of dexmedetomidine while escalating propofol dose and vice versa. We used Cox proportional hazard and multivariable regression adjusted for relevant clinical variable to evaluate the association of sedative dose with 90-day mortality. Measurements and Main Results: Younger patients (598 of 1,177 [50.8%]) received significantly higher doses of both sedatives compared with older patients to achieve comparable sedation depth. On double stratification analysis, escalating infusion rates of propofol to 1.27 mg/kg/h at a steady dexmedetomidine infusion rate (0.54 μg/kg/h) was associated with reduced adjusted mortality in younger but not older patients. This was consistent with multivariable regression modeling (hazard ratio, 0.59; 95% confidence interval, 0.43-0.78; P < 0.0001) adjusted for baseline risk and interaction with dexmedetomidine dose. In contrast, among younger patients, using multivariable regression, escalating dexmedetomidine infusion rate was associated with increased adjusted mortality (hazard ratio, 1.30; 95% confidence interval, 1.03-1.65; P = 0.029). Conclusions: In patients ⩽65 years of age sedated with dexmedetomidine and propofol combination, preferentially increasing the dose of propofol was associated with decreased adjusted 90-day mortality. Conversely, increasing dexmedetomidine may be associated with increased mortality. Clinical trial registered with www.clinicaltrials.gov (NCT01728558).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Shehabi Y, Serpa Neto A, Bellomo R, et al. Dexmedetomidine and Propofol Sedation in Critically Ill Patients and Dose-associated 90-Day Mortality: A Secondary Cohort Analysis of a Randomized Controlled Trial (SPICE III). Am J Respir Crit Care Med. 2023. PMID: 36215171. doi:10.1164/rccm.202206-1208OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。